|
Johnnie White, CMP, has been appointed to the new head of the meetings and educational services division at the Cardiovascular Research Foundation (CRF).
SAN FRANSISCO—An estimated 10,000 transcatheter heart valves have been implanted in patients with critical valvular aortic stenosis, and the researchers, who have their eyes on U.S. approval, are now seeking to standardize the techniques and trial expectations, according to a presentation by Martin B. Leon, MD, at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) symposium.
Drug-eluting stents (DES) showed no difference in real-world results compared with bare-metal stents (BMS) for mortality and MI, for both on-label and off-label usage, according to a meta-analysis involving nearly 200,000 patients published online June 15 in Circulation. The study also compared the rates of target vessel revascularization (TVR).
Orlando, Fla.—A new analysis of the HORIZONS-AMI trial found no increased stent thrombosis with drug-eluting stents (DES) compared with bare-metal stents (BMS)—both shortly after PCI and at one year. It also found that adjunct pharmacologic therapy influenced the risk of stent thrombosis, according to research presented Sunday during the i2 Summit at the American College of Cardiology’s 58th annual scientific session.
Boston Scientific has begun patient enrollment in the PLATINUM clinical trial, which is designed to evaluate its Promus Element everolimus drug-eluting stent (DES).
Written by C.P. Kaiser
You can hardly blink today without hearing the words “conflict of interest.” And with good reason: to preserve the integrity of science despite the source of research funding.
Among the plethora of clinical trials and analysis presented at this year’s Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, a few reports were of particular interest to the interventional cardiology community.
WASHINGTON—After one year, use of a drug-eluting stent (DES) in heart attack patients demonstrated significantly reduced rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of a bare metal stent (BMS), according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
WASHINGTON—Coronary heart disease symptoms presented in the context of a stressful life event were identified as psychogenic when presented by women and organic when presented by men, which could help explain why there is often a delay in the assessment of women with heart disease, according to research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.
|
Amidst the excitement of the Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco this week comes the news that its co-founder, Martin B. Leon, MD, is once again being investigated for potential conflicts of interest and unreported income from medical device makers.
The 21 st annual scientific symposium of the Transcatheter Cardiovascular Therapeutics (TCT) meeting will open on Monday in San Francisco. Gregg W. Stone, MD, immediate past-chairman of the Cardiovascular Research Foundation, which sponsors TCT, highlighted some of the trials and important sessions at next week’s show.
The Cardiovascular Research Foundation (CRF) has appointed William A. Himmelsbach, FACHE, as the foundation's new president and CEO, as well as to its board of directors. He succeeds Marvin L. Woodall, who is retiring.
ORLANDO, Fla.--In patients with ST-elevation MI (STEMI), TAXUS stents significantly reduce neointimal hyperplasia compared to bare-metal stents, but also result in a high frequency of late acquired stent malapposition, according to a substudy of HORIZONS-AMI presented Sunday at the i2 Summit at the American College of Cardiology's (ACC) 58th annual scientific session.
The Women's Heart Health Initiative at the Cardiovascular Research Foundation (CRF) has created a new fellowship dedicated to gender-specific research that will seek to improve the prevention, diagnosis and treatment of heart disease in women.
Sens. Charles Grassley, R-Iowa, and Herb Kohl, D-Wis., have requested that the Cardiovascular Research Foundation (CRF), which sponsors Transcatheter Cardiovascular Therapeutics (TCT), and Columbia University, reveal how medical devicemakers have promoted their products throughout the symposium’s sessions.
The news from this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C., revealed the truth in the words of Jonathan Swift to the interventional community: There is nothing constant in this world but inconsistency.
WASHINGTON—After one year, use of bivalirudin in MI patients, who receive angioplasty, resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding, compared to the standard drug therapy of heparin and glycoprotein IIb/IIIa inhibitors, according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Sen. Herb Kohl, D-Wis., has sent a letter to the president of the American College of Cardiology (ACC) requesting information about the group's recently announced five-year partnership with the Cardiovascular Research Foundation (CRF).
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.